LOW RATES OF MAJOR ADVERSE CARDIAC EVENTS, MALIGNANCIES, AND SERIOUS INFECTIONS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS TREATED WITH APREMILAST FOR ≥156 WEEKS: POOLED ANALYSIS FROM THE ESTEEM AND PALACE 1-3 PHASE 3 TRIALS

LOW RATES OF MAJOR ADVERSE CARDIAC EVENTS, MALIGNANCIES, AND SERIOUS INFECTIONS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS TREATED WITH APREMILAST FOR ≥156 WEEKS: POOLED ANALYSIS FROM THE ESTEEM AND PALACE 1-3 PHASE 3 TRIALS Meeting Abstract

publication date

June 1, 2017

webpage

Web of Science

published in

ANNALS OF THE RHEUMATIC DISEASES Journal

start page

1314

end page

1315

volume

76